Abstract
During the last decades, the advent of biological therapies has revolutionized the management of several immune-mediated inflammatory disorders, as inflammatory bowel diseases, autoimmune arthritis and psoriasis, which significantly impact both quality of life and health care economics. Biological therapies currently available can be divided into two main categories: the tumor necrosis factor-α antagonists (infliximab, adalimumab, etanercept, golimumab, certolizumab pegol) and interleukin 12/23 monoclonal antibodies (ustekinumab).
Biologics, reducing TNFα bioavailability or inhibiting proximal regulators of inflammatory cascade, represent an established therapeutic strategy of inflammatory autoimmune diseases, with remarkable efficacy and a safety profile that is extensively examined and monitored.
The biology and the immunological effects of TNFα, IL-12, IL-23 and related signalling pathways are accurately summarized. The dosing regimens, methods of administration, pharmacodynamics profiles, and side effects of the currently licensed TNFα antagonists and IL12/IL23 inhibitor are discussed in detail.
Keywords: Adverse events, immune-mediated inflammatory disease, TNFα inhibitors, TNF biology, Ustekinumab.
Current Drug Safety
Title:Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts
Volume: 11 Issue: 1
Author(s): E. Molinelli, A. Campanati, G. Ganzetti and A. Offidani
Affiliation:
Keywords: Adverse events, immune-mediated inflammatory disease, TNFα inhibitors, TNF biology, Ustekinumab.
Abstract: During the last decades, the advent of biological therapies has revolutionized the management of several immune-mediated inflammatory disorders, as inflammatory bowel diseases, autoimmune arthritis and psoriasis, which significantly impact both quality of life and health care economics. Biological therapies currently available can be divided into two main categories: the tumor necrosis factor-α antagonists (infliximab, adalimumab, etanercept, golimumab, certolizumab pegol) and interleukin 12/23 monoclonal antibodies (ustekinumab).
Biologics, reducing TNFα bioavailability or inhibiting proximal regulators of inflammatory cascade, represent an established therapeutic strategy of inflammatory autoimmune diseases, with remarkable efficacy and a safety profile that is extensively examined and monitored.
The biology and the immunological effects of TNFα, IL-12, IL-23 and related signalling pathways are accurately summarized. The dosing regimens, methods of administration, pharmacodynamics profiles, and side effects of the currently licensed TNFα antagonists and IL12/IL23 inhibitor are discussed in detail.
Export Options
About this article
Cite this article as:
Molinelli E., Campanati A., Ganzetti G. and Offidani A., Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts, Current Drug Safety 2016; 11 (1) . https://dx.doi.org/10.2174/1574886310666151014115127
DOI https://dx.doi.org/10.2174/1574886310666151014115127 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Purine Nucleoside Phosphorylase: A Potential Target for the Development of Drugs to Treat T-Cell- and Apicomplexan Parasite-Mediated Diseases
Current Drug Targets An Update on JAK Inhibitors
Current Medicinal Chemistry Autoantibodies Associated with Psychiatric Disorders
Current Neurovascular Research Comparative Biochemistry of GH3, GH20 and GH84 β-N-acetyl-Dhexosaminidases and Recent Progress in Selective Inhibitor Discovery
Current Drug Targets Idiopathic Transverse Myelitis and Neuromyelitis Optica: Clinical Profiles,Pathophysiology and Therapeutic Choices
Current Neuropharmacology A Review on Defects of Dendritic Cells in Common Variable Immunodeficiency
Endocrine, Metabolic & Immune Disorders - Drug Targets Manipulating Thymic Apoptosis for Future Therapy of Autoimmune Diseases
Current Pharmaceutical Design TNF, Cell Death and Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmunity in Type 1 Diabetes
Current Stem Cell Research & Therapy APO2L/TRAIL: New Insights in the Treatment of Autoimmune Disorders
Recent Patents on Inflammation & Allergy Drug Discovery The Contrasting Roles of NKT Cells in Tumor Immunity
Current Molecular Medicine Experimental Strategies in Autoimmunity: Antagonists of Cytokines and their Receptors, Nanocarriers, Inhibitors of Immunoproteasome, Leukocyte Migration and Protein Kinases
Current Pharmaceutical Design Crystallization and Preliminary X-Ray Studies of the Fab Fragment from a Humanized Version of the Mouse Anti-Human Fas Antibody Hfe7a
Protein & Peptide Letters Models of Antigen Receptor Activation in the Design of Vaccines
Current Pharmaceutical Design Hepatitis C Viruss Immune Evasion Strategies
Current Immunology Reviews (Discontinued) Pharmacological Targeting of IDO-Mediated Tolerance for Treating Autoimmune Disease
Current Drug Metabolism The Role of CTLA-4 Gene Polymorphisms in Autoimmune Disease Pathogenesis: A 2012 Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Transcription Factors in Autoimmune Diseases
Current Pharmaceutical Design Mouse Models of Autoimmune Diseases: Immune Thrombocytopenia
Current Pharmaceutical Design Recent Developments in the Medicinal Chemistry and Therapeutic Potential of Dihydroorotate Dehydrogenase (DHODH) Inhibitors
Mini-Reviews in Medicinal Chemistry